The global pharmaceutical company Sanofi has seen several significant developments. The company successively sold the rights to its rare immune disorder drug Enjaymo to Recordati for $825 million, propelling its push in rare diseases. As the BIOSECURE Act looms, Sanofi's healthcare bidders are overhauling their offers due to talc concerns. The company offloaded a rare autoimmune drug to Recordati, marking a potential $1 billion deal. With a $72 million infusion from BARDA, Sanofi, in partnership with GSK and CSL, is set to expand the US bird flu vaccine supply. The FDA also favored Sanofi and Regeneron's Dupixent to treat COPD. Vicore hopes to be a significant IPF player with Sanofi aboard. Sanofi also leverages AI in clinical trials and has marked its entry into the red-hot radiopharma space with a $110 million licensing deal. The company's tolebrutinib drug showed a promising 31% delay in MS progression in trials. A new plant in Germany will accommodate a €1.3 billion investment for insulin production, signifying further growth. Sanofi aims for international reach with its Diabetes GLP-1 drug while continuing to invest in healthcare start-ups through the Global Health Unit Impact fund.
Sanofi News Analytics from Thu, 01 Feb 2024 10:55:01 GMT to Sat, 05 Oct 2024 08:37:34 GMT - Rating 7 - Innovation 8 - Information 9 - Rumor 4
